Biogen
 
公司簡況
財務
派息紀錄
盈利預測
股權變動
ETF簡況
 
 
 
公司概覽
業務類別 Drug Manufacturers - General
業務概覽 Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
公司地址 225 Binney Street, Cambridge, MA, USA, 02142
電話號碼 +1 617 679-2000
傳真號碼 +1 302 636-5454
公司網頁 https://www.biogen.com
員工數量 7500
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Ms. Susan H. Alexander Executive Vice President and Chief Legal Officer 美元 954.19K 06/02/2026
Dr. Jane Grogan, PhD Executive Vice President, Head of Research -- 06/02/2026
Dr. Ginger Gregory, PhD Executive Vice President and Chief Human Resources Officer -- 06/02/2026
Ms. Robin C. Kramer Executive Vice President and Chief Financial Officer -- 06/02/2026
Mr. Sean Godbout Vice President, Chief Accounting Officer and Global Corporate Controller -- 06/02/2026
Mr. Adam Keeney, PhD Executive Vice President and Head of Corporate Development -- 06/02/2026
Dr. Priya Singhal, M.D.,M.P.H. Executive Vice President and Head of Development 美元 816.35K 06/02/2026
Mr. Rachid Izzar Executive Vice President, Global Product Strategy and Commercialization -- 06/02/2026
Mr. Christopher A. Viehbacher Director, President and Chief Executive Officer 美元 1.60M 06/02/2026
Ms. Nicole Murphy Executive Vice President, Pharmaceutical Operations and Technology 美元 764.57K 06/02/2026
 
董事會成員
董事會 職務 更新日期
Ms. Susan K. Langer Independent Director 06/02/2026
Ms. Caroline D. Dorsa Chairman of the Board 11/02/2026
Dr. Eric K. Rowinsky,M.D. Independent Director 06/02/2026
Mr. William A. Hawkins, III Independent Director 06/02/2026
Dr. Stephen A. Sherwin, M.D. Independent Director 06/02/2026
Professor Menelas Pangalos, PhD Independent Director 06/02/2026
Dr. Lloyd B. Minor, M.D. Independent Director 06/02/2026
Dr. Maria C. Freire, PhD Independent Director 11/02/2026
Mr. Jesus B. Mantas Independent Director 06/02/2026
Mr. Monish D. Patolawala Independent Director 06/02/2026
Mr. Christopher A. Viehbacher Director, President and Chief Executive Officer 06/02/2026
 
所屬ETF (更新日期: 07/03/2026 04:08)
代號 名稱 佔比% ▼ 持有日期
QLDProShares Ultra QQQ<0.000001%22/12/2025
QLVFlexShares US Quality Low Vol ETF<0.000001%02/09/2025
QNXTiShares Nasdaq-100 ex Top 30 ETF<0.000001%19/12/2025
QQAInvesco QQQ Income Advantage ETF<0.000001%22/12/2025
QQEWFirst Trust Nasdaq-100 Sel Eql Wght ETF<0.000001%21/12/2025
QQHHCM Defender 100 Index ETF<0.000001%07/08/2025
QQMGInvesco ESG NASDAQ 100 ETF<0.000001%22/12/2025
QQQEDirexion NASDAQ-100® Equal Wtd ETF<0.000001%22/12/2025
QQQHNEOS Nasdaq-100 Hdg Eq Inc ETF<0.000001%27/02/2026
QQQINEOS Nasdaq-100(R) High Income ETF<0.000001%22/12/2025
QQQMInvesco NASDAQ 100 ETF<0.000001%22/12/2025
QQXTFirst Trust NASDAQ-100 ex-Tech Sect ETF<0.000001%21/12/2025
QRMIGlobal X NASDAQ 100® Risk Mngd Inc ETF<0.000001%22/12/2025
QSIXPacer Metarus Nasdaq 100 Div Mltpl600ETF<0.000001%22/12/2025
QTRGlobal X NASDAQ 100® Tail Risk ETF<0.000001%22/12/2025
QVMTInvesco S&P S&P 500 Concentrated QVM ETF<0.000001%25/02/2026
QYLDGlobal X NASDAQ 100 Covered Call ETF<0.000001%22/12/2025
QYLGGlobal X Nasdaq 100® Covered Call&Gr ETF<0.000001%22/12/2025
RAASMI 3Fourteen REAL Asset Allocation ETF<0.000001%02/01/2026
RALSProShares RAFI® Long/Short<0.000001%30/04/2022
  1    2    3    4    5    6    7    8    9    10    11    12    13    14   15    16  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.